Purdue and Mallinckrodt resolve OxyContin patent suit
This article was originally published in Scrip
Purdue Pharma and Mallinckrodthave signed an agreement to end their OxyContin (oxycodone controlled-release) tablets patent infringement suit which has been pending in a district court in New York. Mallinckrodt acknowledges the validity and enforceability of Purdue's patents. At the same time, Purdue has agreed to grant Mallinckrodt a royalty-bearing licence to sell limited quantities of versions of 10mg, 20mg, 40mg and 80mg extended-release oxycodone tablets. The District Court for the Southern District of New York has repeatedly ruled in favour of Purdue on the enforceability of its US patents covering OxyContin.